New indications for Merck & Co. Inc.’s Keytruda and Epizyme Inc.’s Tazverik continued the steady run of approvals from the US Food and Drug Administration’s oncology center, with the notable addition of multiple approvals from the Center for Drug Evaluation and Research’s endocrinology and rheumatology review offices.
FDA approval of Eli Lilly & Co